Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis

Diabetes

Volumn 61, Issue 4, 2012, Pages 915-924

  Rajwani, Adil ^a   Ezzat, Vivienne ^b   Smith, Jessica ^a   Yuldasheva, Nadira Y ^a   Duncan, Edward R ^b   Gage, Matthew ^a   Cubbon, Richard M ^a   Kahn, Matthew B ^a   Imrie, Helen ^a   Abbas, Afroze ^a   Viswambharan, Hema ^a   Aziz, Amir ^a   Sukumar, Piruthivi ^a   Vidal Puig, Antonio ^c   Sethi, Jaswinder K ^c   Xuan, Shouhong ^d   Shah, Ajay M ^b   Grant, Peter J ^a   Porter, Karen E ^a   Kearney, Mark T ^a   Wheatcroft, Stephen B ^a   more..

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SERINE; SOMATOMEDIN BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VASODILATATION; WILD TYPE;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; CELLS, CULTURED; DIABETES MELLITUS; ENDOTHELIAL CELLS; GENE DELETION; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MICE; MICE, TRANSGENIC; NITRIC OXIDE; OBESITY; RECEPTOR, INSULIN;

EID: 84859524836     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0963     Document Type: Article

References (53)

1. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with nondiabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36 (Pubitemid 43947203)
2. Danaei G, Finucane MM, Lu Y, et al.; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40
3. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
4. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011;378:182-197
5. Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-637 (Pubitemid 26174707)
6. Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994;42:140-144 (Pubitemid 24336141)
7. Lee PD, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 1997;216:319-357
8. Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 2009;20:153-162
9. Chesik D, De Keyser J, Bron R, Fuhler GM. Insulin-like growth factor binding protein-1 activates integrin-mediated intracellular signaling and migration in oligodendrocytes. J Neurochem 2010;113:1319-1330
10. Gleeson LM, Chakraborty C, McKinnon T, Lala PK. Insulin-like growth factor-binding protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein kinase pathway. J Clin Endocrinol Metab 2001;86:2484-2493 (Pubitemid 32545696)
11. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci U S A 1993;90:10553-10557 (Pubitemid 23347080)
12. Perks CM, Newcomb PV, Norman MR, Holly JM. Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells. J Mol Endocrinol 1999;22:141-150 (Pubitemid 29193102)
13. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994;79:872-878
14. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC. Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 1991;129: 2254-2256
15. Yki-Järvinen H, Mäkimattila S, Utriainen T, Rutanen EM. Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab 1995;80:3227-3232
16. Heald AH, Cruickshank JK, Riste LK, et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001;44: 333-339 (Pubitemid 32234460)
17. Liew CF, Wise SD, Yeo KP, Lee KO. Insulin-like growth factor binding protein-1 is independently affected by ethnicity, insulin sensitivity, and leptin in healthy, glucose-tolerant young men. J Clin Endocrinol Metab 2005;90:1483-1488 (Pubitemid 40464008)
18. Maddux BA, Chan A, De Filippis EA, Mandarino LJ, Goldfine ID. IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance [corrected in: Diabetes Care 2006;29:2571]. Diabetes Care 2006;29:1535-1537 (Pubitemid 44127577)
19. Mohamed-Ali V, Pinkney JH, Panahloo A, Cwyfan-Hughes S, Holly JM, Yudkin JS. Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome. Clin Endocrinol (Oxf) 1999;50:221-228 (Pubitemid 29100010)
20. Rajpathak SN, McGinn AP, Strickler HD, et al. Insulin-like growth factor- (IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res 2008;18:166-173 (Pubitemid 351292519)
21. Travers SH, Labarta JI, Gargosky SE, Rosenfeld RG, Jeffers BW, Eckel RH. Insulin-like growth factor binding protein-I levels are strongly associated with insulin sensitivity and obesity in early pubertal children. J Clin Endocrinol Metab 1998;83:1935-1939 (Pubitemid 28496319)
22. Yeap BB, Chubb SA, Ho KK, et al. IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men. Eur J Endocrinol 2010;162:249-257
23. Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K, Hall K. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 2008;51:1135-1145
24. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002;359:1740-1745 (Pubitemid 34607089)
25. Leinonen ES, Salonen JT, Salonen RM, et al. Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 2002;25:1807-1812 (Pubitemid 41071091)
26. Heald AH, Siddals KW, Fraser W, et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002;51:2629-2636 (Pubitemid 34827416)
27. Wheatcroft SB, Kearney MT, Shah AM, et al. Vascular endothelial function and blood pressure homeostasis in mice overexpressing IGF binding protein-1. Diabetes 2003;52:2075-2082 (Pubitemid 36919801)
28. Crossey PA, Jones JS, Miell JP. Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes 2000;49:457-465 (Pubitemid 30131793)
29. Noronha BT, Li JM, Wheatcroft SB, Shah AM, Kearney MT. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes 2005;54:1082-1089 (Pubitemid 40446322)
30. Duncan ER, Walker SJ, Ezzat VA, et al. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. Am J Physiol Endocrinol Metab 2007;293:E1311-E1319 (Pubitemid 350106599)
31. Wheatcroft SB, Shah AM, Li JM, et al. Preserved glucoregulation but attenuation of the vascular actions of insulin in mice heterozygous for knockout of the insulin receptor. Diabetes 2004;53:2645-2652 (Pubitemid 39299274)
32. Wheatcroft SB, Kearney MT, Shah AM, et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007; 56:285-294
33. Rajkumar K, Modric T, Murphy LJ. Impaired adipogenesis in insulin-like growth factor binding protein-1 transgenic mice. J Endocrinol 1999;162:457-465 (Pubitemid 29447440)
34. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;98:894-898 (Pubitemid 26293305)
35. Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 2001;276:30392-30398
36. Abbas A, Imrie H, Viswambharan H, et al. The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes 2011;60:2169-2178
37. Kido Y, Nakae J, Hribal ML, Xuan S, Efstratiadis A, Accili D. Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance. J Biol Chem 2002;277:36740-36747
38. Wang Y, Nagase S, Koyama A. Stimulatory effect of IGF-I and VEGF on eNOS message, protein expression, eNOS phosphorylation and nitric oxide production in rat glomeruli, and the involvement of PI3-K signaling pathway. Nitric Oxide 2004;10:25-35 (Pubitemid 38410892)
39. Kielczewski JL, Jarajapu YP, McFarland EL, et al. Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res 2009;105:897-905
40. Grant MB, Wargovich TJ, Ellis EA, et al. Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4 and -5 in human atherectomy specimens. Regul Pept 1996;67:137-144 (Pubitemid 26422930)
41. Patel VA, Zhang QJ, Siddle K, et al. Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ Res 2001;88:895-902 (Pubitemid 32441467)
42. Duncan ER, Crossey PA, Walker S, et al. Effect of endothelium-specific insulin resistance on endothelial function in vivo [corrected in: Diabetes 2009;58:511]. Diabetes 2008;57:3307-3314
43. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888-1904 (Pubitemid 43739401)
44. Zhang F, Sjöholm K, Zhang Q. Attenuation of insulin secretion by insulin-like growth factor binding protein-1 in pancreatic beta-cells. Biochem Biophys Res Commun 2007;362:152-157 (Pubitemid 47296305)
45. Dai Z, Xing Y, Boney CM, Clemmons DR, D'Ercole AJ. Human insulin-like growth factor-binding protein-1 (hIGFBP-1) in transgenic mice: characterization and insights into the regulation of IGFBP-1 expression. Endocrinology 1994;135:1316-1327
46. Rajkumar K, Krsek M, Dheen ST, Murphy LJ. Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice. J Clin Invest 1996;98:1818-1825 (Pubitemid 26359199)
47. Leu JI, Crissey MA, Craig LE, Taub R. Impaired hepatocyte DNA synthetic response posthepatectomy in insulin-like growth factor binding protein 1-deficient mice with defects in C/EBP beta and mitogen-activated protein kinase/extracellular signal-regulated kinase regulation. Mol Cell Biol 2003;23:1251-1259 (Pubitemid 36177035)
48. Fernández-Hernando C, Ackah E, Yu J, et al. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab 2007;6:446-457 (Pubitemid 350163050)
49. Kuhlencordt PJ, Gyurko R, Han F, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001;104:448-454 (Pubitemid 32678276)
50. Kaplan RC, McGinn AP, Pollak MN, et al. High insulinlike growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. Am Heart J 2008;155:1006-1012
51. Janszky I, Hallqvist J, Ljung R, Hammar N. Insulin-like growth factor binding protein-1 is a long-term predictor of heart failure in survivors of a first acute myocardial infarction and population controls. Int J Cardiol 2010;138:50-55
52. Wallander M, Norhammar A, Malmberg K, Ohrvik J, Rydén L, Brismar K. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care 2007;30:2343-2348 (Pubitemid 47359045)
53. Mellbin LG, Rydén L, Brismar K, Morgenthaler NG, Ohrvik J, Catrina SB. Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 2010;33:1604-1606